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Purpose or Objective: Low-dose radiotherapy (LDRT) is a 
highly effective treatment in indolent non-Hodgkin 
lymphomas (NHLs). However, a reduced efficacy in aggressive 
lymphomas has never been demonstrated. We aimed to 
assess the effect of histologic type on disease response to 
LDRT. 
 
Material and Methods: Data from a clinical phase-II trial 
using LDRT for palliation in diffuse large B-cell lymphoma 
(DLBCL) patients were compared with clinical outcome of 
patients with follicular lymphoma (FL), marginal zone 
lymphoma (MZ), and mycosis fungoides (MF) which were 
treated with LDRT at our Institution in the same period. LDRT 
consisted of 4 Gy in 2 fractions on symptomatic areas only for 
both DLBCL and indolent NHLs. Bulky disease was defined as 
> 5 cm in maximum diameter. Chemoresistance was defined 
as the failure of chemo to achieve a complete or partial 
response, or as disease relapse after a complete response. 
Clinical response was assessed 21 days after LDRT, and was 
defined as reduction > 50% of maximum diameter of the 
radiated lesions. Response evaluation was performed with 
CT-scan or clinical exam for palpable lesion. Toxicity was 
scored using the CTCAE v3.0. 
 
Results: In all, 35 patients were evaluated. Sixteen were 
male; histologies were 17 DLBCL, 8 FL, 6 MZ, and 4 MF. 
Characteristics were generally balanced between the two 
groups. However, DLBCL patients were more likely to have 
bulky disease and chemoresistance. Median follow up was 7 
months (range, 1 – 49 months). No significative difference 
was noted concerning overall response rate between DLBCL 
and indolent NHLs (overall response rate was 70% (12/17) and 
83% (15/18) for patients with aggressive and indolent forms, 
respectively; p = 0.39), but indolent forms were associated 
with a higher rate of complete response (complete response 
rate was 61% (11/18) and 35% (6/17) for patients with 
indolent and aggressive NHL, respectively; p = 0.09). Only 1 
case of toxicity was noted (grade 2 nausea). The median 
duration of response was 7 months (range, 1 – 35 months). 
Among responders, only 2 patients progressed within the 
radiated field at the time of last follow-up visit. 
 
Conclusion: Efficacy of LDRT for DLBCL and indolent NHL 
patients resulted comparable in terms of overall response 
rate. Complete response rate was higher in the indolent NHL 
population than in the subset of DLBCL patients included in 
the phase II trial. 
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Purpose or Objective: Follicular lymphoma (FL) is an 
indolent disease with a progressive relapsing course. 
Autologous hematopoietic cell transplantation (AHCT) has 
been proven to be effective in treating recurrences. At The 
Ottawa Hospital (TOH), AHCT utilizing total body irradiation 
(TBI) has been used to treat FL patients, who have progressed 
after at least one course of chemotherapy, for over 20 years. 
There are concerns in the literature regarding the use of TBI 
due to the potential for radiation-induced second 
malignancies. However, we hypothesize that TBI based 
conditioning regimens should not lead to excessive second 
cancers. We undertook a review of our large single-institution 
AHCT experience in order to assess patient outcomes and 
rates of second malignancy. 
 
Material and Methods: We retrospectively reviewed 
consecutive patients undergoing AHCT for relapsed FL from 
July 1991 to February 2013. All patients received treatment 
at TOH, a regional tertiary center. The most common pre-
AHCT conditioning regimen was Etoposide 60 mg/kg / 
Melphalan 140 mg/m2 / TBI. Patients received TBI on a linear 
accelerator using high energy photons (10MV or 18MV) and 
utilizing a translating bed technique. 92% received 5 Gy / 
1fraction / 1day, the rest received 12 Gy / 6 fractions / 3 
days. Lung attenuators were used for all patients to maintain 
a homogeneous dose. Patient information was stored in our 
bone marrow transplant registry database. This includes 
baseline characteristics, demographics, outcomes, types and 
dates of second cancers. Descriptive statistics were 
calculated for all relevant demographic variables. Overall 
survival of the cohort was estimated using the Kaplan-Meier 
method. Cumulative incidence of second malignancy was 
calculated; death was a competing risk. 
 
Results: Overall, we evaluated 174 patients with a median 
age of 50 years at transplant. There were 106 men and 68 
women included, and median follow-up was 6.0 years after 
AHCT. Overall survival at 1, 5, 10 and 15 years was 93%, 73%, 
57% and 47% respectively. The median follow-up among 
survivors was 8.3 years. Eighteen of 174 patients (10.3 %) 
developed a second malignancy. Of these, 11 (6.3%) had solid 
tumors, 2 (1.1%) had AML and 5 (2.9%) developed 
myelodysplastic syndrome. Median time to second malignancy 
was 7.2 years, with cumulative incidences of developing 
second cancer at approximately 4.5% and 8.2% at 5 and 10 
years. Solid tumors included breast (2), prostate (3), 
endometrial (1), skin (4) and lung cancers (1). Furthermore, 
82% of patients who developed solid tumors were alive at last 
follow-up. 
 
Conclusion: Our results with AHCT utilizing TBI in the 
management of relapsed FL patients have been very good. 
Indeed, most patients survive more than 10 years after 
treatment. The risk of second cancers is acceptable and 
compares favorably with the published literature. Moreover, 
we suspect screening, particularly for solid tumors post-
treatment, may help detect early treatable second 
malignancies. 
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Purpose or Objective: Mucosa-associated lymphoid tissue 
(MALT) lymphoma can present in several sites in the head and 
neck and is often treated with radiotherapy. MALT lymphoma 
of the salivary and lacrimal glands is >300 fold more common 
in patients with Sjogren’s syndrome (SS) than in the rest of 
the population and tends to be a multifocal process. The 
optimal dose of radiotherapy is not established. The aim of 
this study is to analyse the outcome of radiotherapy for head 
and neck MALT lymphoma in patients with and without SS. 
 
Material and Methods: A retrospective review of 
departmental records identified 26 patients with head & neck 
MALT lymphoma treated with radiotherapy between 2003-
2013. Inclusion criteria were histologically proven MALT 
lymphoma and complete radiotherapy record. The primary 
end-points were objective response rate and response 
